|
|
||||||||
Journal of Lipid Research, Vol 37, 179-191, Copyright © 1996 by Lipid Research, Inc.
DA Winegar, JA Salisbury, SS Sundseth and RL Hawke
The hypothesis that mitochondrial sterol 27-hydroxylase plays a role in the
sterol-mediated down-regulation of LDL receptor activity was evaluated in
HepG2 cells. 27-Hydroxycholesterol was found to be more potent at
suppressing LDL receptor activity than cholesterol (IC50 values of 8 mu M
and 142 mu M for 27-hydroxycholesterol and cholesterol, respectively) when
the sterols were delivered to cells from 2-hydroxypropyl-beta-cyclodextrin
(beta-CD)-solubilized solutions. Cyclosporin, an immunosuppressant which
has been shown to inhibit the 27-hydroxylation of sterols, was used to
assess whether the formation of endogenous 27-hydroxycholesterol was
required for the cholesterol- induced suppression of LDL receptor activity.
Cyclosporin dose- dependently inhibited the 27-hydroxylation of cholesterol
by HepG2 mitochondria (Ki = 0.25 mu M) and HepG2 cell cultures (IC50 = 1 mu
M). At 1 mu M, cyclosporin had no effect on LDL receptor activity, and did
not prevent the suppression of LDL receptor activity caused by: 1) the
addition of beta-CD-solubilized cholesterol, 2) the receptor-mediated
uptake of beta-VLDL, or 3) the inhibition of cholesterol esterification. In
contrast, 10 mu M cyclosporin was found to inhibit the esterification of
cholesterol and to increase the cellular level of free cholesterol
resulting in suppression of LDL receptor activity. These results suggest
that if mitochondrial sterol 27-hydroxylase plays a role in the regulation
of LDL receptor activity, it is not through the formation of potent
regulatory oxysterols, but through its effects on the availability and/or
size of the free cholesterol pool regulating LDL receptor activity.
ARTICLES
Effects of cyclosporin on cholesterol 27-hydroxylation and LDL receptor activity in HepG2 cells
Division of Pharmacokinetics and Drug Metabolism, Glaxo Wellcome Inc., Research Triangle Park, NC 27709, USA.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. Rodriguez-Agudo, S. Ren, P. B. Hylemon, K. Redford, R. Natarajan, A. Del Castillo, G. Gil, and W. M. Pandak Human StarD5, a cytosolic StAR-related lipid binding protein J. Lipid Res., August 1, 2005; 46(8): 1615 - 1623. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hall, P. Hylemon, Z. Vlahcevic, D. Mallonee, K. Valerie, N. Avadhani, and W. Pandak Overexpression of CYP27 in hepatic and extrahepatic cells: role in the regulation of cholesterol homeostasis Am J Physiol Gastrointest Liver Physiol, July 1, 2001; 281(1): G293 - G301. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Schroepfer Jr. Oxysterols: Modulators of Cholesterol Metabolism and Other Processes Physiol Rev, January 1, 2000; 80(1): 361 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wu, Y. H. Zhu, and S. B. Patel Cyclosporin-induced dyslipoproteinemia is associated with selective activation of SREBP-2 Am J Physiol Endocrinol Metab, December 1, 1999; 277(6): E1087 - E1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Luker, K. R. Nilsson, D. F. Covey, and D. Piwnica-Worms Multidrug Resistance (MDR1) P-glycoprotein Enhances Esterification of Plasma Membrane Cholesterol J. Biol. Chem., March 12, 1999; 274(11): 6979 - 6991. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |